dorsaVi Ltd engages in the development and sale of motion analysis technologies in Australia, Europe, and the United States.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.019|
|52 Week High||AU$0.018|
|52 Week Low||AU$0.08|
|1 Month Change||-13.64%|
|3 Month Change||-29.63%|
|1 Year Change||-57.78%|
|3 Year Change||-72.86%|
|5 Year Change||-95.58%|
|Change since IPO||-95.25%|
Recent News & Updates
A Look At dorsaVi's (ASX:DVL) CEO Remuneration
This article will reflect on the compensation paid to Andrew Ronchi who has served as CEO of dorsaVi Ltd ( ASX:DVL...
|DVL||AU Biotechs||AU Market|
Return vs Industry: DVL underperformed the Australian Biotechs industry which returned 1.7% over the past year.
Return vs Market: DVL underperformed the Australian Market which returned 20.2% over the past year.
Stable Share Price: DVL is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: DVL's weekly volatility has decreased from 20% to 7% over the past year.
About the Company
dorsaVi Ltd engages in the development and sale of motion analysis technologies in Australia, Europe, and the United States. The company provides ViMove, a wearable sensor technology, which provides patient care and exercise plans, patient engagement and recovery programs, and rehabilitation programs; ViSafe, a wearable sensor technology that tracks, analyzes, and reports how workforce moves and reviews and pinpoints unsafe work practices that leads to workplace injury; and myViSafe technology for organizations and on-site clinicians to identify and mitigate injury risk in the workplace and drive behavioral changes. It also offers ViPerform, a wearable and wireless movement sensor technology that offers objective data to assess risk of sport injury, and guides athletic training and recovery programs; telehealth solutions; and professional suites.
dorsaVi Fundamentals Summary
|DVL fundamental statistics|
Is DVL overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|DVL income statement (TTM)|
|Cost of Revenue||AU$166.33k|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.0058|
|Net Profit Margin||-108.52%|
How did DVL perform over the long term?See historical performance and comparison
Is dorsaVi undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate DVL's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate DVL's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: DVL is unprofitable, so we can't compare its PE Ratio to the Global Biotechs industry average.
PE vs Market: DVL is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate DVL's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: DVL is good value based on its PB Ratio (3.1x) compared to the AU Biotechs industry average (4.8x).
How is dorsaVi forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as dorsaVi has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has dorsaVi performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: DVL is currently unprofitable.
Growing Profit Margin: DVL is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: DVL is unprofitable, and losses have increased over the past 5 years at a rate of 0.6% per year.
Accelerating Growth: Unable to compare DVL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: DVL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (46.5%).
Return on Equity
High ROE: DVL has a negative Return on Equity (-93.76%), as it is currently unprofitable.
How is dorsaVi's financial position?
Financial Position Analysis
Short Term Liabilities: DVL's short term assets (A$4.8M) exceed its short term liabilities (A$1.5M).
Long Term Liabilities: DVL's short term assets (A$4.8M) exceed its long term liabilities (A$1.4M).
Debt to Equity History and Analysis
Debt Level: DVL's debt to equity ratio (73.8%) is considered high.
Reducing Debt: DVL's debt to equity ratio has increased from 0.01% to 73.8% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: DVL has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: DVL has less than a year of cash runway if free cash flow continues to grow at historical rates of 20.3% each year.
What is dorsaVi current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate DVL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate DVL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if DVL's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if DVL's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of DVL's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Dr. Andrew James Ronchi, B.App.Sci. (Physio), PhD (RMIT Eng), GAICD, co-founded dorsaVi Ltd. and serves as its Managing Director. He has been Chief Executive Officer of dorsaVi Ltd since February 2008 and...
CEO Compensation Analysis
Compensation vs Market: Andrew's total compensation ($USD217.91K) is about average for companies of similar size in the Australian market ($USD302.06K).
Compensation vs Earnings: Andrew's compensation has been consistent with company performance over the past year.
Experienced Board: DVL's board of directors are seasoned and experienced ( 13.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: DVL insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 51.9%.
dorsaVi Ltd's employee growth, exchange listings and data sources
- Name: dorsaVi Ltd
- Ticker: DVL
- Exchange: ASX
- Founded: 2008
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$6.677m
- Shares outstanding: 351.43m
- Website: https://www.dorsavi.com
Number of Employees
- dorsaVi Ltd
- 86 Denmark Street
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/20 15:29|
|End of Day Share Price||2021/10/20 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.